Author:
Alemnji George A,Ngulefac Gisele A,Ndumbe Peter M,Asonganyi Tazoacha
Abstract
As programs to prevent and care for HIV-infected persons are scaled-up in Africa, there is the need for continuous evaluation of the performance of test kits that could best support these programs. The present study evaluated the sensitivity, specificity, ease of use, and cost of AWARE TM Blood Serum Plasma (BSP) and Oral Mucosal Transudate (OMT) Rapid HIV-1/2 test kits using real-time and archived samples of HIV-infected persons from Cameroon. Matched whole blood and OMT specimens were collected prospectively from HIV-positive and HIV-negative persons from different regions of Cameroon and tested using the AWARE TM BSP and OMT test kits, respectively. These results were compared to the gold standard that included a combination of Determine HIV-1/2 and Enzygnost HIV-1/2. The BSP Rapid test kit was further evaluated using well characterized panels of HIV-2 and HIV-1 group O samples. Cost and end-user analysis of the OMT test kit was done by comparing its actual cost, consumables, safety, bench time and manipulation with other test kits. Of the 732 matched samples, 412 (56.3%) and 320 (43.7%) were from females and males, respectively. Of these samples, 23 (3.1%) gave discordant results between Determine HIV-1/2 and Enzygnost HIV1/2 and were excluded from the analysis. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the AWARETM BSP were 100%. The AWARETM OMT had 98.8% sensitivity, 98.9% specificity, 98.0% PPV and 99.4% NPV. The results of a well-characterized archived panel of HIV-2 (n=7) and HIV-1 group O (n=3) samples using the AWARETM BSP Rapid test kit gave 100% concordance. Total per patient cost of the AWARE OMT rapid test kit was US$4.72 compared to a mean cost of US $7.33 + 0.11 for the other test kits. Both the AWARETM BSP and OMT Rapid test kits demonstrated high sensitivities and specificities on all samples tested and were well adapted for use in resource-constrained settings with high HIV heterogeneity such as Cameroon. The AWARE TM HIV-1/2 OMT Rapid test kit appears to be the cheapest, safest and easiest to use compared with other available test kits.
Publisher
Bentham Science Publishers Ltd.
Subject
Virology,Infectious Diseases,Public Health, Environmental and Occupational Health
Reference27 articles.
1. Jacobson LP, Li R, Phair J, et al.
Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression
Am J Epidemiol
2002;
155
: 760-0.
2. Opravil M, Ledergerber B, Furrer H, et al.
Swiss HIV Cohort Study Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 106 /l
AIDS
2002;
16
: 371-81.
3. Tamashiro H, Maskill W, Emmanuel J, Fauquex A, Sato P, Heymann D.
Reducing the cost of HIV antibody testing
Lancet
1993;
342
: 7-90.
4. Constantine NT, Zink H.
HIV testing technologies after two decades of evolution
Indian J Med Res
2005;
121
: 19-38.
5. UNAIDS/WHO.
Guidelines for using HIV testing technologies in surveillance: Selection, evaluation and implementation
UNAIDS/ 0122E WHO/CDS/CSR/EDC
2001;
16
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献